이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

iSpecimen 대차 대조표 상태

재무 상태 기준 확인 3/6

iSpecimen 의 총 주주 지분은 $6.8M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $12.5M 및 $5.7M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$2.56m
주식	US$6.81m
총 부채	US$5.70m
총 자산	US$12.51m

최근 재무 상태 업데이트

Recent updates

Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)

Jan 04

Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term

Aug 07

Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump

Apr 18

iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price

Mar 31

iSpecimen: High Growth Marketplace At A Discount

Jul 07

iSpecimen raises $18M via Nasdaq IPO

Jun 21

재무 상태 분석

단기부채: ISPC 의 단기 자산 ( $5.3M )은 단기 부채( $5.7M ).

장기 부채: ISPC 에는 장기 부채가 없습니다.

부채 대 자본 내역 및 분석

부채 수준: ISPC 부채가 없습니다.

부채 감소: ISPC 현재 부채가 없지만 해당 기간에 대한 데이터가 없기 때문에 5년 전과 비교할 수 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: ISPC 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 25.3 %의 역사적 비율로 계속 감소할 경우 ISPC 의 현금 활주로는 1년 미만입니다.

iSpecimen 대차 대조표 상태

재무 상태 기준 확인 3/6

주요 정보

최근 재무 상태 업데이트

Nasdaq Grants an Additional 180 Calendar Day Period, or Until October 7, 2024 to iSpecimen to Regain Compliance with the Minimum Bid Price Requirement

iSpecimen Inc. Receives a Deficiency Notice from the Nasdaq Stock Market

Recent updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

iSpecimen Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Nasdaq Grants an Additional 180 Calendar Day Period, or Until October 7, 2024 to iSpecimen to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 16%

Full year 2023 earnings: EPS and revenues miss analyst expectations

iSpecimen Inc. to Report Fiscal Year 2023 Results on Mar 13, 2024

iSpecimen Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.

Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)

Ispecimen Inc. Announces Executive Changes

Consensus estimates of losses per share improve by 15%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

iSpecimen Inc. Provides Revenue Guidance for Third Quarter 2023

iSpecimen Inc. to Report Q3, 2023 Results on Nov 02, 2023

iSpecimen Inc. Receives a Deficiency Notice from the Nasdaq Stock Market

iSpecimen Inc. Launches Next-Day Quote Service for Medical Researchers and Biospecimen Providers

Ispecimen Expands Provider Network to Enhance Support for Women's Health Research

iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers

Consensus revenue estimates fall by 23%

Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term

New minor risk - Shareholder dilution

Price target decreased by 38% to US$5.00

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

iSpecimen Inc. to Report Q2, 2023 Results on Aug 02, 2023

iSpecimen Inc. Receives A Letter of Resignation from Christopher Ianelli to Resign as A Director

Less than half of directors are independent

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump

Full year 2022 earnings: EPS and revenues exceed analyst expectations

iSpecimen Appoints Eric Langlois as Chief Revenue Officer

Secretary & Director exercised options to buy US$108k worth of stock.

iSpecimen Inc. Appoints Tracy Curley as Chief Executive Officer

Now 21% undervalued after recent price drop

iSpecimen Inc. Appoints Joseph J. Basile to Board of Directors

Less than half of directors are independent

iSpecimen Inc. Announces Board Changes

Price target decreased to US$7.63

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$7.63

iSpecimen Inc. Launches New Open Feasibilities Dashboard on the Ispecimen Marketplace Platform to Enhance Biospecimen Fulfillment for Global Partner Network

iSpecimen Inc. to Report Q3, 2022 Results on Nov 08, 2022

iSpecimen Inc. Announces Executive Changes

iSpecimen names finance chief Tracy Curley as interim CEO

Consensus revenue estimates fall by 13%

iSpecimen Inc. (NASDAQ:ISPC) Analysts Just Slashed This Year's Estimates

Price target decreased to US$9.83

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$10.83

iSpecimen GAAP EPS of -$0.30 misses by $0.02, revenue of $2.3M misses by $0.55M

iSpecimen Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

iSpecimen Inc. to Report Q1, 2022 Results on May 10, 2022

iSpecimen Inc. Unveils Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently

iSpecimen Inc., Annual General Meeting, May 25, 2022

iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price

Founder exercised options to buy US$210k worth of stock.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

iSpecimen Inc. to Report Q4, 2021 Results on Feb 17, 2022

iSpecimen Inc. announced that it has received $20.999988 million in funding

iSpecimen Inc. announced that it expects to receive $20.999988 million in funding

Chief Financial Officer recently bought US$52k worth of stock

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$1.33 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.86 loss per share (vs US$1.33 loss in 2Q 2020)